Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs reported a net loss of Rs 4,381.42 lakhs for FY2026 (standalone) compared to a net profit of Rs 692.43 lakhs in FY2025. Revenue from operations declined to Rs 2,321.27 lakhs from Rs 3,175.76 lakhs year-on-year. The company swung to a loss primarily due to high cost of materials (Rs 1,247.82 lakhs) and elevated finance costs (Rs 1,620.82 lakhs). EBITDA turned negative at approximately Rs (3,014) lakhs. Current borrowings increased significantly to Rs 9,455.80 lakhs (from Rs 7,095.51 lakhs), while cash and cash equivalents dropped sharply to Rs 67.25 lakhs (from Rs 257.33 lakhs). The auditor issued a clean/unmodified opinion with no going concern flag. The company has a pending merger of its wholly-owned subsidiary with itself, with NCLT hearing scheduled for June 2, 2026.
The company swung from profit to a substantial loss with deteriorating cash position and rising debt, which is a significant concern for shareholders. The clean audit opinion provides some comfort, but the operational and financial stress needs close monitoring.